AEQUOR’S NOVEL MOLECULES COUNTER BIOFILM ASSOCIATED WITH HOSPITAL-ACQUIRED INFECTIONS
Bacteria and fungi can form biofilms that stick to surfaces inside the human body. This process enables microbial cells to become tolerant and resistant to antibiotics, thus making infections more difficult to treat.
Pathogenic bacterial biofilms are recognized as causing or exacerbating numerous chronic infections, including cystic fibrosis pneumonia, chronic otitis media, and recurrent urinary tract infections.The consequences for patients and healthcare providers include increased morbidity, extended hospital stays, higher hospital charges, and increased in-hospital mortality.
Current antimicrobials and antibiotics are designed to kill only free-floating microorganisms and cannot remove the biofilm once it forms. After discovering 30+ novel small molecules that remove bacterial and fungal biofilm in minutes and prevent its formation for days, Aequor is looking to develop antibiofilm agents and new antibiotics. The company expects ultimately to gain approval for a large portfolio of new drugs that combat broad-spectrum AMR infections and diseases.